V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Biogen Executive Compensation (FY25)

BIIB · Executive and director compensation, fiscal 2022 to 2025
Data as of September 7, 2026Latest filing (8-K): June 10, 2026
282 figures on this page: 271 cited to the filing that reported them, 11 calculated from figures it prints. See the citations
Christopher Viehbacher, President and Chief Executive Officer, received $23,646,004 in total compensation for fiscal 2025, and Viehbacher's total moved 2.2% lower from the $24,166,665 reported for fiscal 2024. Meanwhile, the company reported a chief executive pay ratio of 113:1 for fiscal 2025, against median employee compensation of $208,335. Separately, the say-on-pay proposal drew 93.7% of votes cast including abstentions in favor at the meeting held June 9, 2026 for fiscal 2025, and the disclosed peer group names AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., BioMarin Pharmaceutical Inc. and Bristol-Myers Squibb Company, among others.
Chief executive, fiscal 2025
◇
Christopher Viehbacher
Median of the other named officers
$7,571,387
5 officers, excluding the chief executive
Latest say-on-pay support
=
June 9, 2026
Chief executive pay ratio
◇
To the median employee
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Christopher Viehbacher: $24,166,665 → $23,646,004 (2.2% lower)
CEO pay ratio: 132:1 → 113:1 (14.4% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is Biogen's chief executive and what were they paid?
Christopher Viehbacher, President and Chief Executive Officer, received $23,646,004 in total compensation for fiscal 2025. Viehbacher's total moved 2.2% lower from the $24,166,665 reported for fiscal 2024.
What was Biogen's say-on-pay result?
The say-on-pay proposal drew 93.7% of votes cast including abstentions in favor at the meeting held June 9, 2026 for fiscal 2025.
Which companies are in Biogen's peer group?
The disclosed peer group names AbbVie Inc., Alnylam Pharmaceuticals, Inc., Amgen Inc., BioMarin Pharmaceutical Inc. and Bristol-Myers Squibb Company, among others.
What is Biogen's chief executive pay ratio?
The company reported a chief executive pay ratio of 113:1 for fiscal 2025, against median employee compensation of $208,335.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Viehbacher
President and Chief Executive Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael McDonnell
Executive Vice President, Chief Operating Officer
◇—◇—◇◇◇◇
Susan Alexander
Executive Vice President, Chief Legal Officer
◇—◇—◇◇◇◇
Nicole Murphy
Head of Pharmaceutical Operations and Technology
◇—◇—◇—◇◇
Rachid Izzar
Head of Global Product Strategy & Commercialization
◇—◇—◇—◇◇
Christopher Viehbacher
President and Chief Executive Officer
◇———◇◇◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Viehbacher
President and Chief Executive Officer
◇—◇—◇◇◇◇
Michael McDonnell
Executive Vice President, Chief Operating Officer
◇—◇—◇◇◇◇
Susan Alexander
Executive Vice President, Chief Legal Officer
◇—◇—◇—◇◇
Priya Singhal
Head of Development and Chief Medical Officer
◇—◇—◇◇◇◇
Nicole Murphy
Head of Pharmaceutical Operations and Technology
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Christopher Viehbacher
President and Chief Executive Officer
◇—◇—◇—◇◇
Susan Alexander
Executive Vice President, Chief Legal Officer
◇—◇—◇◇◇◇
Nicole Murphy
Head of Pharmaceutical Operations and Technology
◇—◇—◇—◇◇
Priya Singhal
Head of Development
◇◇◇—◇—◇◇
Robin Kramer
Executive Vice President and Chief Financial Officer
◇—◇—◇—◇◇
Michael McDonnell
Former Executive Vice President and Chief Financial Officer
Departed during or after this year
◇—————◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Christopher ViehbacherPSU◇—————◇
Christopher ViehbacherPSU◇——◇——◇
Christopher ViehbacherRSU◇——◇——◇
Nicole MurphyPSU◇——◇——◇
Nicole MurphyPSU◇——◇——◇
Nicole MurphyRSU◇——◇——◇
Priya SinghalRSU◇——◇——◇
Priya SinghalPSU◇——◇——◇
Priya SinghalPSU◇——◇——◇
Robin KramerPSU◇——◇——◇
Robin KramerRSU◇——◇——◇
Robin KramerPSU◇——◇——◇
Susan AlexanderPSU◇——◇——◇
Susan AlexanderPSU◇——◇——◇
Susan AlexanderRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Nicole MurphyRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Priya SinghalRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
Robin KramerPSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Susan AlexanderRSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Christopher ViehbacherPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Caroline D. Dorsa
Board chair
◇◇————◇
William A. Hawkins
◇◇————◇
Jesus B. Mantas
◇◇———◇◇
Maria C. Freire
◇◇———◇◇
Eric K. Rowinsky
◇◇————◇
Monish Patolawala
◇◇————◇
Stephen A. Sherwin
◇◇————◇
Susan K. Langer
◇◇————◇
Menelas Pangalos
◇◇————◇
Lloyd Minor
◇◇————◇
Christopher A. Viehbacher served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as restricted stock units.
Stock ownership guideline: 5x cash retainer (Chair: 5x combined Chair + Board retainer)

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • Alnylam Pharmaceuticals, Inc. ALNY
  • Amgen Inc. AMGN
  • BioMarin Pharmaceutical Inc. BMRN
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences Inc. GILD
  • Incyte Corporation INCY
  • Jazz Pharmaceuticals plc JAZZ
  • Merck & Co, Inc. MRK
  • Moderna, Inc. MRNA
  • Neurocrine Biosciences, Inc. NBIX
  • Regeneron Pharmaceuticals, Inc. REGN
  • United Therapeutics Corporation UTHR
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 9, 2026=◇◇◇
2024June 17, 2025=◇◇◇
2023June 20, 2024=◇◇◇
2022June 26, 2023=◇◇◇
2021June 15, 2022=◇◇◇
2020June 2, 2021=◇◇◇
2019June 3, 2020=◇◇◇
2018June 19, 2019=◇◇◇
2017June 12, 2018=◇◇◇
2016June 7, 2017=◇◇◇
2015June 8, 2016=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Biogen files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Biogen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Biogen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Biogen's disclosed peer group is defensible, who names Biogen back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
282 figures on this page: 271 cited to the filing that reported them, 11 calculated from figures it prints.
271 cited to the filing
11 calculated from the filing

Documents cited

  1. 0000950157-26-000700
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-187303
    2025 Director Compensation · 2025 Grants of Plan-Based Awards · CEO Pay Ratio · Director Compensation · and 2 more sections
  3. 0000875045-25-000023
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-25-097747
    Summary Compensation Table
  5. 0001193125-24-167938
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-118313
    Summary Compensation Table
  7. 0000875045-23-000024
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-127639
    Summary Compensation Table
  9. 0001193125-22-177791
  10. 0000875045-21-000032
  11. 0000875045-20-000013
  12. 0000875045-19-000023
  13. 0000875045-18-000012
  14. 0001193125-17-200127
  15. 0000875045-16-000058
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Biogen executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/BIIB (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Biogen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Biogen discloses

The companies named in BIIB's own disclosed peer group.

AbbVie Inc.Alnylam Pharmaceuticals, Inc.Amgen Inc.BioMarin Pharmaceutical Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences Inc.Incyte CorporationJazz Pharmaceuticals plcMerck & Co, Inc.Moderna, Inc.Neurocrine Biosciences, Inc.Regeneron Pharmaceuticals, Inc.United Therapeutics CorporationVertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy